Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
about
Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infectionsIn Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains.In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014.Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor CombinationsChanges in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing Isolates.Carbapenem-Resistant Enterobacteriaceae Infections in Children.Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.Incidence of Extended-Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella Infections in the United States: A Systematic Literature Review.Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections.Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?The rapid spread of carbapenem-resistant Enterobacteriaceae.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world.Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae InfectionsCeftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies.Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants.Outbreak of Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae: Are We at the End of the Road?First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3.Pharmacokinetics of Ceftazidime-Avibactam in Two Patients With KPC-Producing Klebsiella pneumoniae Bacteremia and Renal Impairment.Treatment of Hospital or Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Enterobacteriaceae: Leveraging Molecular Resistance Testing and Combination Therapy to Improve Outcomes.Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae ST307.Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity.How to manage Pseudomonas aeruginosa infections.β-lactam/β-lactamase inhibitor combinations: an updateActivity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015
P2860
Q28069563-38D8E1AA-2229-44EE-A6FD-39C2DBA20F66Q36571892-B20D7026-AA0E-405C-963D-10AF1F2B8886Q36888062-357AF6BE-D3B7-4F41-9354-6E9B8A9360BAQ36933469-6F77BCBF-9A15-4384-9790-AAA8DC2568E9Q37023324-DB2EDC9B-ACA5-4E32-B836-E8DADDA8EFAAQ37055016-873EFEB0-4152-40EA-BEB2-091BC0F80637Q37120191-0A424AF3-AE4E-4978-9BA6-EF6031806B4EQ37154718-ED6F367A-1063-4B87-8755-B2526E154FA0Q37287753-03D29A11-9437-4EC5-A163-5F18B10A5D38Q38595451-46D35A63-6150-4C7E-99F2-402605B35A0DQ38652231-32718C88-B147-46B8-A02F-A31490B3C61FQ38740494-364CAE1C-4868-4F87-880B-1A1DAEEC7608Q38797485-2D33C834-3D0E-4157-97D5-470738461F96Q38875315-D5D9F356-5DDE-4DD1-80FA-8AEC50CD47C1Q38975480-11B352F7-87A9-47DA-81CA-5F6DF69C7DE6Q39027434-0DF3C007-D9D1-42F5-8C02-074E32F7F6D5Q39120027-088EE485-3B14-45DC-9FFD-13640D0C7254Q40196563-55739CF3-4D7A-441A-8D31-7C17CB5CA648Q40392497-1D63F2D1-6E40-4C13-B8C6-FE9573428DC6Q40432497-F0CB42E5-3858-45C4-AE2C-1684E7624A67Q40616586-7A778594-F8D6-465F-990C-D2D484225321Q40916464-148D2701-8248-4978-92BD-439D2729CB9FQ41094925-F34F2030-AE59-40A1-A171-84991828B0B0Q41098656-B96C335C-E6DD-4907-AF33-C06C9898D691Q42102553-DAB9C71A-1D3C-40FB-BFA2-D7E12C30FA7BQ42638031-C895071E-B07C-47BB-9CEA-E704300F5B7FQ45199771-1235B0B0-2C07-4DB9-896B-4029D107E520Q46018544-E4CACAC6-2221-4AB9-9A5D-171281806314Q46264986-490DD05F-AD6D-4B7C-81C0-8AF5F4E4D6F4Q47139448-9FA212B9-703F-42BD-BD52-B41BE09893EFQ47269615-C0ED31E8-82AB-4A8E-B598-F45796DCC027Q48355592-7B7DD33A-8363-4BB2-837B-AD2440EDA26AQ54977074-C24FCF50-C4EF-4A30-8777-707981BEC9B8Q57133147-69CB1667-7139-4462-A062-906EE7CBB011Q57211457-B7EF0CE5-7E7B-43B6-9FCD-FD5B5B935B8A
P2860
Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ceftazidime-avibactam activity ...... β-lactamase-producing strains.
@ast
Ceftazidime-avibactam activity ...... β-lactamase-producing strains.
@en
type
label
Ceftazidime-avibactam activity ...... β-lactamase-producing strains.
@ast
Ceftazidime-avibactam activity ...... β-lactamase-producing strains.
@en
prefLabel
Ceftazidime-avibactam activity ...... β-lactamase-producing strains.
@ast
Ceftazidime-avibactam activity ...... β-lactamase-producing strains.
@en
P2093
P2860
P356
P1476
Ceftazidime-avibactam activity ...... β-lactamase-producing strains.
@en
P2093
Janet C Mills
Ronald N Jones
Sarah E Costello
P2860
P304
P356
10.1128/AAC.00163-15
P407
P577
2015-04-06T00:00:00Z